By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CoLucid Pharmaceuticals, Inc. 

902 North Capitol Avenue
Suite 302
Indianapolis  Indiana  46204  U.S.A.
Phone: 317-684-6703 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
CoLucid Pharma Announces Second Quarter 2015 Results And Corporate Highlights 8/13/2015 9:57:04 AM
CoLucid Pharma Announces Appointment Of Marvin L. White To Board Of Directors 7/13/2015 7:08:22 AM
CoLucid Pharma Announces Pricing Of IPO 5/6/2015 7:25:08 AM
CoLucid Pharma Announces Initiation Of First Phase 3 Pivotal Trial Of Lasmiditan In Migraine 4/28/2015 7:29:01 AM
After Exiting RTP, CoLucid Pharma Files with SEC for $86M IPO 3/31/2015 7:59:37 AM
CoLucid Pharma Raises $37M For Migraine Treatment 3/31/2015 7:39:32 AM
CoLucid Pharma Exits RTP And Relocates To Massachusetts 3/26/2015 6:32:49 AM
CoLucid Pharmaceuticals, Inc. Appoints Matthew Dallas As Chief Financial Officer And Treasurer 2/9/2015 9:57:25 AM
CoLucid Pharmaceuticals, Inc. Announces Agreement From The FDA On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Lasmiditan In Migraine Including Patients With Risk Factors For Cardiovascular Disease 5/7/2014 8:19:43 AM
CoLucid Pharmaceuticals, Inc. and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine 10/23/2013 9:51:59 AM
123
//-->